<DOC>
	<DOC>NCT02951988</DOC>
	<brief_summary>This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).</brief_summary>
	<brief_title>A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) criteria for MDD Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Screening Have no more than partial response (&lt; 50% improvement) to ongoing treatment with a protocolallowed antidepressant If female of childbearing potential, have a negative serum βhuman chorionic gonadotropin (βhCG) pregnancy test. DSM5based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Screening Lifetime history of meeting DSM5 criteria for: 1. Schizophrenia spectrum or other psychotic disorder 2. Bipolar or related disorder 3. Major neurocognitive disorder 4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study 5. Dissociative disorder 6. Posttraumatic stress disorder 7. MDD with psychotic features Significant suicide risk, as judged by the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>